{"id":"alvac-hiv-vcp1521-aidsvax","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, induration)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3672477","moleculeType":"Small molecule","molecularWeight":"317.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALVAC-HIV vCP1521 is a recombinant canarypox virus expressing HIV-1 genes that primes the immune system by inducing CD8+ T-cell responses. AIDSVAX is a recombinant gp120 envelope protein that serves as a booster to enhance antibody responses and broaden immune recognition. Together, this prime-boost strategy aims to generate both cell-mediated and humoral immunity to prevent HIV infection or control viral replication.","oneSentence":"A combination HIV vaccine that uses a recombinant canarypox vector (ALVAC-HIV vCP1521) as a prime followed by a recombinant gp120 protein boost (AIDSVAX) to elicit cellular and humoral immune responses against HIV.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:00.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 prevention in at-risk populations"},{"name":"HIV-1 therapeutic vaccine in chronically infected individuals"}]},"trialDetails":[{"nctId":"NCT06484335","phase":"PHASE1","title":"RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-03-27","conditions":"HIV Infections, PLWH, ART","enrollment":48},{"nctId":"NCT04658667","phase":"PHASE1","title":"HIV Vaccine in HIV-uninfected Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2022-02-03","conditions":"HIV","enrollment":81},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":"HIV Infections","enrollment":1512},{"nctId":"NCT03284710","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-19","conditions":"HIV Infections","enrollment":132},{"nctId":"NCT02968849","phase":"PHASE2, PHASE3","title":"Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-26","conditions":"HIV Infections","enrollment":5404},{"nctId":"NCT05769569","phase":"PHASE1","title":"Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2023-09-01","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT02771730","phase":"PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults","status":"TERMINATED","sponsor":"Emergent BioSolutions","startDate":"2015-03","conditions":"Healthy Volunteer, HIV Vaccine","enrollment":20},{"nctId":"NCT03122223","phase":"PHASE1, PHASE2","title":"Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-16","conditions":"HIV Infections","enrollment":160},{"nctId":"NCT02852005","phase":"PHASE1","title":"Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT03618056","phase":"PHASE1","title":"Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-19","conditions":"HIV Infections, Systemic Lupus Erythematosus","enrollment":1},{"nctId":"NCT02404311","phase":"PHASE1, PHASE2","title":"A Safety and Immune Response Study of 2 Experimental HIV Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-02-02","conditions":"HIV Infection","enrollment":252},{"nctId":"NCT00001096","phase":"PHASE1","title":"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00000813","phase":"PHASE1","title":"A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":28},{"nctId":"NCT00001076","phase":"PHASE1","title":"A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00000847","phase":"PHASE1","title":"A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00000871","phase":"PHASE2","title":"A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":420},{"nctId":"NCT00000904","phase":"PHASE1","title":"Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00001072","phase":"PHASE1","title":"A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":140},{"nctId":"NCT00001055","phase":"PHASE1","title":"A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":76},{"nctId":"NCT00001136","phase":"PHASE1","title":"A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":60},{"nctId":"NCT00011011","phase":"PHASE1, PHASE2","title":"Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-02","conditions":"HIV Infections","enrollment":94},{"nctId":"NCT00098163","phase":"PHASE1","title":"Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00001090","phase":"PHASE1","title":"A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT00007423","phase":"PHASE1","title":"Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00026624","phase":"PHASE1","title":"Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00000884","phase":"PHASE1","title":"A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":84},{"nctId":"NCT00000879","phase":"PHASE1","title":"A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":48},{"nctId":"NCT00000946","phase":"PHASE1","title":"A Study to Test the Safety of Three Experimental HIV Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":40},{"nctId":"NCT01927835","phase":"PHASE1","title":"Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT01964937","phase":"PHASE1","title":"Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00007332","phase":"PHASE2","title":"Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":330},{"nctId":"NCT02207920","phase":"PHASE1","title":"Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-07","conditions":"HIV Infections","enrollment":104},{"nctId":"NCT00027261","phase":"PHASE1","title":"Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":110},{"nctId":"NCT00076063","phase":"PHASE1, PHASE2","title":"A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":"HIV Infections","enrollment":174},{"nctId":"NCT00011037","phase":"PHASE2","title":"ALVAC-HIV vCP1452 Alone and Combined With MN rgp120","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":160},{"nctId":"NCT01931358","phase":"PHASE2","title":"Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E","status":"UNKNOWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2013-09-24","conditions":"HIV Infections","enrollment":360},{"nctId":"NCT01435135","phase":"PHASE2","title":"Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144","status":"UNKNOWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-04","conditions":"HIV Infections","enrollment":162},{"nctId":"NCT01933685","phase":"PHASE2","title":"Study of Immune Responses Induced by a HIV Vaccine","status":"UNKNOWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2014-07-03","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT02109354","phase":"PHASE1","title":"Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2013-06-18","conditions":"HIV Infection","enrollment":202},{"nctId":"NCT00223080","phase":"PHASE3","title":"HIV Vaccine Trial in Thai Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2003-10","conditions":"HIV Infection","enrollment":16402},{"nctId":"NCT03391375","phase":"PHASE1","title":"Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial","status":"COMPLETED","sponsor":"EuroVacc Foundation","startDate":"2017-03-15","conditions":"HIV/AIDS","enrollment":49},{"nctId":"NCT00337181","phase":"","title":"Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2006-05","conditions":"HIV-1","enrollment":114},{"nctId":"NCT00056797","phase":"PHASE2","title":"Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-03","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT02376582","phase":"PHASE1","title":"Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS","status":"COMPLETED","sponsor":"EuroVacc Foundation","startDate":"2014-09","conditions":"HIV/AIDS","enrollment":72},{"nctId":"NCT00894114","phase":"PHASE1","title":"A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-05","conditions":"HIV-1 Infection","enrollment":250},{"nctId":"NCT01799954","phase":"PHASE1","title":"Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2012-08","conditions":"HIV Infections","enrollment":96},{"nctId":"NCT00006509","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00076817","phase":"PHASE1","title":"Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections, HIV Seronegativity","enrollment":18},{"nctId":"NCT00219362","phase":"PHASE2","title":"Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients","status":"COMPLETED","sponsor":"Objectif Recherche Vaccins SIDA","startDate":"2004-04","conditions":"HIV Infection","enrollment":65},{"nctId":"NCT00196651","phase":"PHASE2","title":"HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection","status":"TERMINATED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2000-08","conditions":"HIV Infection","enrollment":60},{"nctId":"NCT00013572","phase":"PHASE1","title":"HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults","status":"UNKNOWN","sponsor":"Walter Reed Army Institute of Research (WRAIR)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":36},{"nctId":"NCT00006327","phase":"PHASE3","title":"Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand","status":"COMPLETED","sponsor":"VaxGen","startDate":"1999-03","conditions":"HIV Infections, HIV Seronegativity","enrollment":2500},{"nctId":"NCT00002402","phase":"PHASE1","title":"A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines","status":"COMPLETED","sponsor":"VaxGen","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00002441","phase":"PHASE3","title":"Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection","status":"COMPLETED","sponsor":"VaxGen","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":5000},{"nctId":"NCT00004579","phase":"PHASE1","title":"A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection","status":"COMPLETED","sponsor":"Walter Reed Army Institute of Research (WRAIR)","startDate":"1998-04","conditions":"HIV Infections, HIV Seronegativity","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ALVAC-HIV (vCP1521) >106 CCID50 per 1 mL dose","AIDSVAX® B/E","Bivalent HIV gp120 vaccine subtype B (MN), and E (A244)"],"phase":"phase_3","status":"active","brandName":"ALVAC-HIV vCP1521 + AIDSVAX","genericName":"ALVAC-HIV vCP1521 + AIDSVAX","companyName":"U.S. Army Medical Research and Development Command","companyId":"u-s-army-medical-research-and-development-command","modality":"Biologic","firstApprovalDate":"","aiSummary":"A combination HIV vaccine that uses a recombinant canarypox vector (ALVAC-HIV vCP1521) as a prime followed by a recombinant gp120 protein boost (AIDSVAX) to elicit cellular and humoral immune responses against HIV. Used for HIV-1 prevention in at-risk populations, HIV-1 therapeutic vaccine in chronically infected individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}